Browsing by Author "Cabrera, Daniel"

Now showing 1 - 16 of 16
  • No Thumbnail Available
    Item
    A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD
    (2024) Thakral, Nimish; Desalegn, Hailemichael; Diaz Piga, Luis Antonio; Cabrera, Daniel; Loomba, Rohit; Arrese Jiménez, Marco Antonio; Arab Verdugo, Juan Pablo
    The new nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasizes a positive diagnosis based on cardiometabolic risk factors. This definition is not only less stigmatizing but also allows for subclassification and stratification, thereby addressing the heterogeneity of what was historically referred to as nonalcoholic fatty liver disease. The heterogeneity within this spectrum is influenced by several factors which include but are not limited to demographic/dietary factors, the amount of alcohol use and drinking patterns, metabolic status, gut microbiome, genetic predisposition together with epigenetic factors. The net effect of this dynamic and intricate system-level interaction is reflected in the phenotypic presentation of MASLD. Therefore, the application of precision medicine in this scenario aims at complex phenotyping with consequent individual risk prediction, development of individualized preventive strategies, and improvements in the clinical trial designs. In this review, we aim to highlight the importance of precision medicine approaches in MASLD, including the use of novel biomarkers of disease, and its subsequent utilization in future study designs.
  • Thumbnail Image
    Item
    Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis
    (2017) Cabrera, Daniel; Wree, Alexander; Povero, Davide; Solís, Nancy; Hernández, Alejandra; Pizarro Rojas, Margarita Alicia; Moshage, Han; Torres Montes, Paula Javiera; Feldstein, Ariel E.; Cabello Verrugio, Claudio Alejandro; Brandan, Enrique; Barrera Martínez, Francisco Javier; Arab Verdugo, Juan Pablo; Arrese Jiménez, Marco
  • Thumbnail Image
    Item
    Assessment of hepatic fatty acids during non-alcoholic steatohepatitis progression using magnetic resonance spectroscopy
    (2021) Xavier, Aline; Zacconi, Flavia C. M.; Santana Romo, Fabián Mauricio; Eykyn, Thomas R.; Lavin, Begona; Phinikaridou, Alkystis; Botnar, Rene; Uribe, Sergio; Esteban Oyarzun, Juan; Cabrera, Daniel; Arrese, Marco; Andia, Marcelo E.
    Abstract: Introduction and objectives: Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver abnormalities including steatosis, steatohepatitis, fibrosis, and cirrhosis. Liver biopsy remains the gold standard method to determine the disease stage in NAFLD but is an invasive and risky procedure. Studies have previously reported that changes in intrahepatic fatty acids (FA) composition are related to the progression of NAFLD, mainly in its early stages. The aim of this study was to characterize the liver FA composition in mice fed a Choline-deficient L-amino-defined (CDAA) diet at different stages of NAFLD using magnetic resonance spectroscopy (MRS). Methods: We used in-vivo MRS to perform a longitudinal characterization of hepatic FA changes in NAFLD mice for 10 weeks. We validated our findings with ex-vivo MRS, gas chromatography-mass spectrometry and histology. Results: In-vivo and ex-vivo results showed that livers from CDAA-fed mice exhibit a significant increase in liver FA content as well as a change in FA composition compared with control mice. After 4 weeks of CDAA diet, a decrease in polyunsaturated and an increase in monounsaturated FA were observed. These changes were associated with the appearance of early stages of steatohepatitis, confirmed by histology (NAFLD Activity Score (NAS) = 4.5). After 10 weeks of CDAA-diet, the liver FA composition remained stable while the NAS increased further to 6 showing a combination of early and late stages of steatohepatitis. Conclusion: Our results suggest that monitoring lipid composition in addition to total water/fat with MRS may yield additional insights that can be translated for non-invasive stratification of high-risk NAFLD patients.
  • Thumbnail Image
    Item
    Central Role of Transforming Growth Factor Type Beta 1 in Skeletal Muscle Dysfunctions: An Update on Therapeutic Strategies
    (2018) Abrigo, Johanna; Simon, Felipe; Cabrera, Daniel; Cordova, Gonzalo; Trollet, Capucine; Cabello Verrugio, Claudio Alejandro
  • Thumbnail Image
    Item
    High Fat Diet-Induced Skeletal Muscle Wasting Is Decreased by Mesenchymal Stem Cells Administration : Implications on Oxidative Stress, Ubiquitin Proteasome Pathway Activation, and Myonuclear Apoptosis
    (2016) Abrigo, Johanna; Rivera, Juan Carlos; Aravena, Javier; Cabrera, Daniel; Simon, Felipe; Ezquer, Fernando; Ezquer, Marcelo; Cabello Verrugio, Claudio Alejandro
  • No Thumbnail Available
    Item
    Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease—Authors' reply
    (2024) Idalsoaga Ferrer, Francisco Javier; Diaz Piga, Luis Antonio; Ayares Campos, Gustavo Ignacio; Cabrera, Daniel; Chahuan Abde, Javier Nicolas; Monrroy Bravo, Hugo Alfonso; Halawi, Houssam; Arrese Jiménez, Marco Antonio; Arab Verdugo, Juan Pablo
  • Thumbnail Image
    Item
    Long-Term, Fructose-Induced Metabolic Syndrome-Like Condition Is Associated with Higher Metabolism, Reduced Synaptic Plasticity and Cognitive Impairment in Octodon degus
    (2018) Rivera, Daniela S.; Lindsay, Carolina B.; Codocedo Henríquez, Juan Francisco; Carreño, Laura E.; Cabrera, Daniel; Arrese Jiménez, Marco; Vio Lagos, Carlos P.; Bozinovic Kuscevic, Francisco; Inestrosa Cantín, Nibaldo
  • No Thumbnail Available
    Item
    Mineralocorticoid receptor modulation by dietary sodium influences NAFLD development in mice
    (ELSEVIER ESPANA, 2021) Cabrera, Daniel; Rao, Isabel; Raasch, Fabiola; Solis, Nancy; Pizarro, Margarita; Freire, Mariela; De Urturi, Diego Saenz; Ramirez, Carolina A.; Triantafilo, Nicolas; Leon, Jonathan; Riquelme, Arnoldo; Barrera, Francisco; Baudrand, Rene; Aspichueta, Patricia; Arrese, Marco; Arab, Juan P.
    Introduction and Objectives: Nonalcoholic-fatty-liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome (MetS). Mineralocorticoid receptor (MR) activation is associated with increased risk of MetS but few studies have assessed the role of liver MR on NAFLD. We aimed to evaluate the effect of MR modulation by sodium intake in liver injury in experimental models of NAFLD.
  • Thumbnail Image
    Item
    Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease
    (2024) Desalegn, Hailemichael; Farias Siel, Renata Francisca; Hudson, David; Idalsoaga Ferrer, Francisco Javier; Cabrera, Daniel; Díaz Piga, Luis Antonio; Arab Verdugo, Juan Pablo
    Steatotic liver disease (SLD), including metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), is the primary cause of illness and mortality. In particular, MASLD affects more than 30% of the global population, while ALD accounts for 5.1% of all diseases and injuries worldwide. The SLD spectrum includes a variety of clinical conditions, from mild fatty liver and inflammation to different stages of liver fibrosis. Additionally, both conditions (MASLD and ALD) can be complicated by hepatocellular carcinoma (HCC), while around one-third of ALD patients can also develop at least one alcohol associated hepatitis (AH) episode. Both of these diseases are also associated with multiple extrahepatic complications, such as cardiovascular disease, chronic kidney disease, and malignancies. In MASLD, the rapid rise in global obesity and type 2 diabetes mellitus (T2DM) prevalence due to Westernized lifestyles has led to an increase in the prevalence of MASLD. Thus, the prevention and control of cardiometabolic risk factors (CMRFs) are the cornerstone of its treatment. Hypertension and atherogenic dyslipidemia are also important CMRFs associated with MASLD. Susceptible individuals with MASLD are adversely affected by even a small amount of alcohol consumption (though there is no agreed definition of a small amount), increasing the risk of severe outcomes and a faster progression of liver disease. This review explores factors that play a role in the development of SLD, especially focusing on the management of CMRFs and levels of alcohol use to prevent liver disease progression.
  • Thumbnail Image
    Item
    Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy
    (2013) Morales France, María Gabriela; Gutiérrez Pérez, Jaime Agustín; Cabello Verrugio, Claudio Alejandro; Cabrera, Daniel; Lipson, Kenneth E.; Goldschmeding, Roel; Brandan, Enrique
  • Thumbnail Image
    Item
    Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-beta signalling
    (2014) Acuña, María José; Pessina, Patrizia; Olguín Marín, Hugo César; Cabrera, Daniel; Vio Lagos, Carlos P.; Bader, Michael; Muñoz Canoves, Pura; Santos, Robson A.; Cabello Verrugio, Claudio Alejandro; Brandan, Enrique
  • Thumbnail Image
    Item
    Review article: Oesophageal disorders in chronic liver disease
    (WILEY, 2024) Idalsoaga Ferrer, Francisco Javier; Diaz Piga, Luis Antonio; Ayares Campos, Gustavo Ignacio; Cabrera, Daniel; Chahuan Abde, Javier Nicolas; Monrroy Bravo, Hugo Alfonso; Halawi, Houssam; Arrese Jimenez, Marco Antonio; Arab Verdugo, Juan Pablo
    Background: Oesophageal disorders and chronic liver disease are common worldwide and significantly impact quality of life. The intricate link between these conditions, including how oesophageal disorders like GERD, Barrett's oesophagus and oesophageal cancer affect and are affected by chronic liver disease, remains poorly understood. Aims: To review the relationship between oesophageal disorders and chronic liver disease, evaluating epidemiology, pathophysiology and therapeutic factors. Methods: We reviewed the literature on the relationship between oesophageal disorders and chronic liver disease, including cirrhosis, using the PubMed database Results: Oesophageal disorders such as gastroesophageal reflux disease, Barrett's oesophagus, oesophageal cancer, oesophageal motor disorders and oesophageal candidiasis are prevalent among individuals with cirrhosis, exacerbating the burden of liver disease. These diseases have a multifaceted symptomatology and pathogenic basis, posing a significant challenge in cirrhotic patients that necessitates careful diagnosis and management. Additionally, therapies frequently used for these diseases, such as proton pump inhibitors, require careful consideration in cirrhotic patients due to potential adverse effects and altered pharmacokinetics. Managing oesophageal disorders in cirrhotic patients requires a cautious approach due to possible interactions with medications and the risk of adverse effects. Furthermore, symptoms associated with these conditions are often exacerbated by common interventions in patients with cirrhosis, such as band ligation for oesophageal varices. Conclusions: Oesophageal disorders are common in cirrhosis and increase the disease burden. These conditions require careful management due to complex symptoms and treatment risks. Proton pump inhibitors and other therapies must be used cautiously, as cirrhosis interventions can worsen symptoms.
  • Thumbnail Image
    Item
    Sarcopenia in a mice model of chronic liver disease: role of the ubiquitin–proteasome system and oxidative stress
    (2018) Campos, Fabián; Abrigo, Johanna; Aguirre, Francisco; Garcés, Bruno; Arrese Jiménez, Marco; Karpen, Saúl; Cabrera, Daniel; Andía Kohnenkampf, Marcelo Edgardo; Simon, Felipe; Cabello Verrugio, Claudio Alejandro
  • Thumbnail Image
    Item
    The pro-fibrotic connective tissue growth factor ( CTGF/CCN2) correlates with the number of necrotic-regenerative foci in dystrophic muscle
    (2018) Gabriela Morales, Maria; Jose Acuna, Maria; Cabrera, Daniel; Goldschmeding, Roel; Brandan, Enrique
  • Thumbnail Image
    Item
    Transforming Growth Factor Beta Type I Role in Neurodegeneration: Implications for Alzheimer's Disease
    (2018) Estrada, Lisbell D.; Oliveira-Cruz, Luciana; Cabrera, Daniel
  • Thumbnail Image
    Item
    Triggering and resolution of inflammation in NASH
    (2018) Schuster, Susanne; Cabrera, Daniel; Arrese Jiménez, Marco; Feldstein, Ariel E.